<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">In the past, vaccines were developed against SARS-CoV and MERS-CoV, but none of them has been clinically approved for use in humans [
 <xref ref-type="bibr" rid="CR63">63</xref>]. Currently, several vaccination strategies have been undergoing against SARS-CoV using vaccine candidates including inactivated virus, a live-attenuated virus, viral vectors, subunit vaccines, recombinant proteins, DNA vaccines, etc. across the world. Additionally, many other options are being explored for the treatment of COVID-19 patients, including plasma therapy. Recently, convalescence plasma therapy in which the immunoglobulin of cured COVID-19 patients is injected into a severe patient as a treatment option is explored in India, China, and the USA. Table 
 <xref rid="Tab1" ref-type="table">1</xref> shows the status of recent clinical trials of vaccines against SARS-CoV-2 infection. Table 
 <xref rid="Tab2" ref-type="table">2</xref> shows the current status of the clinical trials of vaccines and candidate therapy for cytokine release syndrome (CRS) against SARS-CoV-2 infection.
</p>
